Gedea Biotech to Start EpHect Clinical Trial for Antibiotic-free Treatment of Women with Vulvo Vaginal Candidiasis
PRESS RELEASE Gedea Biotech today announces that it has received regulatory approval from the Ethics Committee and the Swedish Medical Products Agency and will start the EpHect clinical study of its lead product, pHyph, a vaginal tablet for topical treatment. The open-labelled study is designed to…
Gedea Biotech wins the "Rapidus company of the year" award
PRESS RELEASE
Gedea Biotech has been awarded the prestigious award "Rapidus Company of the Year". The ceremony…